Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial
Volume
388
Pagination
239 - 247
DOI
10.1016/S0140-6736(16)00380-9
Journal
LANCET
Issue
ISSN
0140-6736